非小细胞肺癌患者血浆纤维蛋白原检测的临床意义

目的探讨非小细胞肺癌（NSCLC）患者血浆纤维蛋白原水平与肺癌临床病理特征关系及预后的相关性。方法对55例NSCLC患者及20例健康人的血浆纤维蛋白原分别进行测定。结果NSCLC患者血浆纤维蛋白原水平显著高于健康对照组（P〈0．01），肺癌患者血浆纤维蛋白原水平与患者的病理类型、TNM分期之间无明显关系。NSCLC患者血浆纤维蛋白原水平与其生存期之间有显著的负相关（r=-0．37，P〈0．01）。结论NSCLC患者存在血浆纤维蛋白原水平增高，血液存在高凝状态；血浆纤维蛋白原水平与患者的生存期呈负相关，血浆纤维蛋白原是反映NSCLC患者预后的重要指标。

Clinical significance of plasma fibrinogen level detection in non-small cell lung cancer patients

Objective To study the relationship between plasma fibrinogen level on pathophysiological characteristics and prognosis in patients with non-small cell lung cancer. Methods The plasma levels of fibrinogen were detected in fifty-five patients with non-small cell lung cancer and twenty normal controls. Results The plasma levels of fibrinogen in patients with non-small cell lung cancer were significantly higher than those of normal controls（ P 〈 0. 001 ）. The plasma levels of fibrinogen in patients with non-small cell lung cancer were not related to histological classification or P-TNM stages. The plasma levels of fibrinogen in patients with non-small cell lung cancer were negatively correlated to the survival span（ r = -0.37, P〈0.01）. Conclusions Elevation of plasma levels of fibrinogen exists in patients with non-small cell lung cancer. The elevated plasma fib- rinogen level may be associated with hypercoagulability state; the plasma levels of fibrinogen were negatively correlated to the survival span in patients with non-small cell lung cancer and they were important marker of prognosis of patients with non-small cell lung cancer.